Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D02DVK
|
||||
Former ID |
DIB001875
|
||||
Drug Name |
CV-9201
|
||||
Synonyms |
CV-9201-1; CV-9201-2; CV-9201-3; CV-9201-4; CV-9201-5; RNA-based vaccine (NY-ESO-1, MAGE-C1/CT7, MAGE-C2/CT10, NSCLC), CureVac
|
||||
Drug Type |
Vaccine
|
||||
Indication | Non-small cell lung cancer [ICD10:C33-C34] | Phase 1/2 | [522696] | ||
Company |
CureVac GmbH
|
||||
Target and Pathway | |||||
Target(s) | 5T4 ONCOFETAL antigen | Target Info | [550441] | ||
Melanoma-associated antigenC2 | Target Info | [550441] | |||
Baculoviral IAP repeat-containing protein 5 | Target Info | [550441] | |||
Cancer/Testis Antigen MAGE-C1/CT7 | Target Info | [550442] | |||
NY-ESO-1 | Target Info | [550441] | |||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Angiogenesis | ||||
Pathway Interaction Database | Aurora B signaling | ||||
Validated targets of C-MYC transcriptional activation | |||||
FOXM1 transcription factor network | |||||
Aurora A signaling | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.